Workflow
Securities and Investment Fraud
icon
Search documents
INVESTIGATION ALERT: Edelson Lechtzin LLP Announces an Investigation of Nutex Health Inc. (NASDAQ: NUTX) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm
Prnewswire· 2025-07-25 22:07
Company Overview - Nutex Health Inc. is a healthcare services company that develops and operates micro-hospitals and outpatient facilities, manages independent physician associations through a cloud-based platform, and owns and leases healthcare real estate across the United States [2]. Allegations and Concerns - On July 22, 2025, short seller Blue Orca Capital published a report raising concerns about Nutex's relationship with HaloMD, a third-party vendor recently sued for allegedly engaging in a "coordinated fraudulent scheme" to defraud insurance companies [3]. - The report claims that HaloMD assisted Nutex in generating "unsustainably high" reimbursement rates through the arbitration process outlined in the No Surprises Act (NSA), which is designed to protect patients from unexpected medical bills [3]. Market Reaction - Following the publication of the Blue Orca report, Nutex's stock price fell by $11.18 per share, or 10.05%, closing at $100.01 per share on July 22, 2025 [4].
INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation Of BellRing Brands, Inc. (NYSE: BRBR) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm
Prnewswire· 2025-07-07 03:32
Company Overview - BellRing Brands, Inc. is a consumer nutrition company that produces and sells ready-to-drink protein shakes, powders, bars, and other nutrition products under brands such as Premier Protein, Dymatize, and PowerBar [3]. Allegations of Wrongdoing - On May 6, 2025, BellRing disclosed during its quarterly earnings call that it anticipated a reduction in retailer inventory levels for the third quarter of 2025. The company projected "Q3 net sales growth of low-single-digits with Premier Protein the main driver and all others flat to down" [4]. - Following this announcement, BellRing's stock price experienced a significant decline, falling by $14.88 per share, or 18.97%, to close at $63.55 per share on the same day [4]. Legal Investigation - Edelson Lechtzin LLP is investigating potential violations of federal securities laws involving BellRing, stemming from allegations of providing misleading business information to the investing public [1].
INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation Of Lineage, Inc. (NASDAQ: LINE) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm
Prnewswire· 2025-07-07 03:30
Company Overview - Lineage, Inc. is the largest temperature-controlled warehouse real estate investment trust (REIT) globally, operating over 450 cold-storage facilities across North America, Europe, and the Asia-Pacific [3]. Allegations and Financial Performance - Edelson Lechtzin LLP is investigating potential violations of federal securities laws involving Lineage, stemming from allegations of providing misleading business information to investors [1]. - On July 24, 2024, Lineage completed its initial public offering of 56,882,051 shares at $78.00 per share [4]. - On April 30, 2025, Lineage reported a 2.7% decrease in total revenue, amounting to $1.29 billion for the quarter, attributing this decline to more normal seasonal trends after elevated inventory levels in previous years [4]. - Following the revenue report, Lineage's stock price fell by $8.26 per share, or 14.62%, closing at $48.23 per share on April 30, 2025 [4].
INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation Of Semler Scientific, Inc. (NASDAQ: SMLR) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm
Prnewswire· 2025-06-05 02:53
Company Overview - Semler Scientific, Inc. is a healthcare technology company focused on developing and marketing products for the early detection and management of chronic diseases, particularly through its flagship vascular testing device, QuantaFlo [3]. Allegations and Impact - On February 28, 2025, Semler filed its 2024 annual report with the SEC, revealing that the Department of Justice was considering a False Claims Act complaint regarding insurance reimbursement claims related to the QuantaFlo testing device [4]. - Following this disclosure, Semler's stock price dropped by $4.03 per share, representing a decline of 9.4%, closing at $38.89 per share on March 3, 2025 [4]. Legal Investigation - Edelson Lechtzin LLP is investigating potential violations of federal securities laws involving Semler, stemming from allegations of providing potentially misleading business information to investors [1].